First positive health technology assessments for novel oral anticoagulant Pradaxa®

Boehringer IngelheimThe Scottish Medicines Consortium (SMC) has accepted Pradaxa® (dabigatran etexilate) for routine use within the National Health Service (NHS) of Scotland for its currently licensed indication: the prevention of venous thromboembolic events in adults who have undergone total hip or knee replacement surgery. The European Commission granted marketing authorisation for Pradaxa® in all 27 EU member states in March 2008.

Also the Danish Institute for Rational Pharmacotherapy (IRF) which belongs to the Danish Medicines Agency has endorsed Pradaxa® as a good alternative to low molecular weight heparins (LMWH) both with respect to efficacy and ease of use.

These decisions on Pradaxa® are the first by European health technology assessment bodies and their positive outcomes are likely to be viewed favourably by decision makers considering the implementation and reimbursement of Pradaxa® across the EU as they indicate Pradaxa® has fulfilled all clinical and cost-effectiveness criteria necessary for use within the NHS in Scotland and clinical criteria necessary for use in Denmark.

Data from the phase III RE-NOVATE™ and RE-MODEL™ studies showed oral, once daily administration of both 150 and 220 mg Pradaxa® was as effective and safe as injectable enoxaparin (40 mg) in preventing venous thromboembolism (VTE) and all cause mortality following total hip and total knee replacement surgery. In contrast to low molecular weight heparins (LMWH), which require subcutaneous injection, Pradaxa® is administered as a fixed, oral dose making it significantly easier to administer both in the hospital setting and, more importantly, in the home setting after discharge. Unlike both LMWH and warfarin, Pradaxa® does not require monitoring.

Patients undergoing hip and knee replacement surgery are at particularly high risk of developing VTE. Without thromboprophylaxis, up to 60 percent of orthopaedic surgery patients have been shown to develop DVT (deep vein thrombosis; including asymptomatic thrombi), and 0.2-10 percent are at risk of a potentially fatal PE (pulmonary embolism) according to previous studies. It is estimated that 543,454 deaths in Europe per year are VTE-related, more than double the number from breast cancer, prostate cancer, HIV/AIDS and road traffic accidents combined.

Professor Simon Frostick, Professor of Orthopaedics at the University of Liverpool, UK said: "We know that thromboprophylaxis after orthopaedic surgery is crucial to protect patients from potentially life-threatening thrombi. Now, with Pradaxa® as a new therapeutic option, we have an effective oral, once-daily anticoagulant with a good efficacy and safety profile to facilitate convenient thromboprophylaxis both in and out of hospital."

The registered charity AntiCoagulation Europe (ACE) which works to prevent thrombosis and provide information for patients also welcomed the decision. Executive Director Eve Knight said: "This could mean saving lives. Pradaxa® is potentially a huge benefit for patients. One of the reasons why patients are not given thromboprophylaxis is that they have to have heparin which has to be injected. Following hospital discharge, many patients have to learn to self-inject which may result in inadequate treatment duration due to poor compliance. Pradaxa® is so much more convenient; just two capsules once a day."

Pradaxa® has a rapid onset and offset of action and a predictable anticoagulation effect. It prevents thrombus formation by specifically and selectively inhibiting thrombin, the central and essential enzyme in the coagulation cascade that enables conversion of fibrinogen into fibrin. In contrast to warfarin, Pradaxa® exhibits no drug-food interactions and has a low potential for drug-drug interactions.

Boehringer Ingelheim continues to evaluate the efficacy and safety of Pradaxa® in a range of thromboembolic disease conditions. RE-VOLUTION™ is an extensive clinical trial programme involving more than 38,000 patients worldwide. Recent progress includes the announcement in January 2008 of the completion of enrolment of 18,114 patients in RE-LY™, the largest stroke prevention atrial fibrillation outcomes trial to date. Other ongoing studies are evaluating the efficacy and safety of Pradaxa® in the treatment of acute VTE, the secondary prevention of VTE and prevention of cardiac events in patients with acute coronary syndrome.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

For more information, visit www.boehringer-ingelheim.com.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

SMi Group announces the 9th Annual RNA Therapeutic…

21 - 22 February 2018, London, UK. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]